Dendritic cell therapy with CD137L-DC-EBV-VAX in locally recurrent or metastatic nasopharyngeal carcinoma (NPC).
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
Saved in:
Main Authors: | Walsh, Robert John, Nickles, Emily Pauline, Li, Yating, Dharmadhikari, Bhushan, Koh, Mickey, Ho, Liam Pock, Chan, Marieta, Koh, Liang Piu, Poon, Michelle Li Mei, Tan, Lip Kun, Huang, Yiqing, Ang, Yvonne Li'en, Chong, Wan Qin, Asokumaran, Yugarajah, Loh, Kwok Seng, Soo, Ross A, Lim, Chwee Ming, Schwarz, Herbert, Goh, Boon Cher |
---|---|
Other Authors: | MEDICINE |
Format: | Conference or Workshop Item |
Published: |
LIPPINCOTT WILLIAMS & WILKINS
2023
|
Subjects: | |
Online Access: | https://scholarbank.nus.edu.sg/handle/10635/239137 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | National University of Singapore |
Similar Items
-
Dendritic cell therapy with CD137L-DC-EBV-VAX in locally recurrent or metastatic nasopharyngeal carcinoma is safe and confers clinical benefit
by: Nickles, Emily, et al.
Published: (2023) -
The role of nk cells in ebv infection and ebv-associated npc
by: Png, Yi Tian, et al.
Published: (2022) -
Anti-CD137 Cancer Immunotherapy Suppresses Tumor Growth-Letter
by: Dharmadhikari, Bhushan, et al.
Published: (2023) -
CD137L dendritic cells induce potent response against cancer-associated viruses and polarize human CD8(+) T cells to Tc1 phenotype
by: Dharmadhikari, Bhushan, et al.
Published: (2023) -
CD137L- DENDRITIC CELLS HAVE A NOVEL INFLAMMATORY PHENOTYPE AND INDUCE A POTENT TC1 RESPONSE AGAINST EPSTEIN-BARR VIRUS
by: BHUSHAN DHARMADHIKARI
Published: (2017)